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Diabetes Lowers Aerobic Capacity in Heart Failure
To the Editor: Patients with chronic heart failure (CHF) due to
left ventricular (LV) systolic dysfunction develop skeletal muscle
alterations that contribute to lower peak aerobic capacity (1).
Patients with type 2 diabetes develop skeletal muscle alterations
similar to those of patients with CHF (2). To test the hypothesis
that diabetes may further reduce peak aerobic capacity in patients
with CHF, we prospectively measured peak oxygen uptake (peak
VO2) in 156 diabetic and nondiabetic patients with CHF who were
matched for age and gender.
A total of 156 patients met inclusion/exclusion criteria and
agreed to participate in the study. We first identified 204 patients
with CHF and diabetes among the 689 patients with LV ejection
fraction 40% in our CHF clinic and then attempted to match
these 204 diabetic patients for age and gender to the 485 remaining
nondiabetic patients. We found age and gender matches for 106 of
the 204 patients. Informed consent and complete data were
obtained in 78 of the 106 matched patients. Inclusion criteria
included: steady clinical state, ability to perform a maximal exercise
test, and therapy consistent with current CHF guidelines. Exclu-
sion criteria were: exertional angina or arrhythmias; systolic or
diastolic blood pressure 160 and 90 mm Hg, respectively; joint,
pulmonary, or peripheral arterial disease; participation in a training
program; and active tobacco use. Glycosylated hemoglobin was
measured in all patients. They had all undergone coronary angiog-
raphy. Chronic kidney disease was defined by a creatinine clear-
ance 50 ml/min (3). All patients were familiar with exercise
testing and measurement of expired gas.
Patients who met inclusion and exclusion criteria underwent
evaluation of baseline physical activity. Plasma B-type natriuretic
peptide (BNP) level and peak VO2 were determined within one
week of evaluation of physical activity. The average number of
daily steps was used to quantify baseline physical activity (4). It was
recorded daily and averaged over seven consecutive days. Ejection
fraction was assessed by echocardiography. Plasma levels of BNP
were measured using the triage immunoassay (Biosite Inc., San
Diego, California). Peak VO2 was measured during a symptom-
limited treadmill exercise test. Patients who discontinued exercis-
ing for other than shortness of breath and fatigue or did not reach
a respiratory exchange ratio 1.0 were excluded. Peak VO2 was
compared in diabetics and nondiabetics using the t test for two
independent samples. Multiple linear regression analysis was
performed to assess the effect of diabetes on peak VO2 controlling
for hypertension, coronary artery disease (CAD), chronic kidney
disease, BNP plasma level, LV ejection fraction, physical activity,
and glycosylated hemoglobin. We aimed to have a minimum of 15
patients for each parameter that we anticipated to include in our
regression model.
Baseline characteristics and medications are summarized in
Table 1. Hypertension and CAD were more prevalent in diabetics
than in nondiabetics. Plasma BNP level, ejection fraction, body
mass index, prevalence of chronic kidney disease, number of daily
steps, and therapeutic regimen (except for aspirin) were similar in
diabetics and nondiabetics. Peak VO2 was substantially lower in
diabetic than in nondiabetic patients: 13.1 (SD 3.6) versus 18.9
(SD 4.2) ml/kg/min (p  0.001) (Fig. 1). Peak heart rate and
ventilatory threshold were similar in diabetics and nondiabetics.
The difference in peak VO2 between diabetics and nondiabetics
was 5.5 ml/kg/min (p  0.001) after controlling for baseline
characteristics.
Our data extend the findings of Guazzi et al. (5) to a larger and
more controlled patient population. Our data also provide the first
evidence that diabetes is an independent determinant of peak VO2
in patients with CHF. Guazzi et al. (5) studied 40 diabetic and
nondiabetic patients with CHF. Half of the patients were receiving
angiotensin-converting enzyme inhibitors, and none were receiv-
ing beta-adrenergic blockade. Guazzi et al. (5) did not measure
baseline physical activity nor consider whether differences in
comorbid conditions could account for the lower peak VO2 of
diabetic patients. The difference in peak VO2 was lower in the
Guazzi et al. (5) study than in ours: 3.0 versus 5.5 ml/kg/min.
Tighter diabetes control with aggressive insulin therapy may have
Table 1. Characteristics and Medications
Diabetic
n  78
Nondiabetic
n  78
Statistical
Significance
p Value
Age (yrs) 61.6  9.7 61.6  9.7 —
Men (%) 74.4 74.4 —
Physical activity
(number of steps)
8,068  4,169 8,012  4,051 0.89
BMI (kg/m2) 27.4  2.3 26.9  2.7 0.58
LVEF (%) 32.0  13.0 33.5  10.0 0.26
Hgb (g/dl) 13.2  1.6 13.2  1.9 0.96
BNP level (pg/ml) 194.0  366.7 109.5  209.7 0.34
HgbA1c (%) 7.4  1.1 5.0  0.1 0.00
CAD (%) 70.5 52.4 0.01
HTN (%) 78.2 61.9 0.02
History of tobacco
use (%)
51.3 53.2 0.79
CKD (%) 35.9 32.1 0.73
Atrial fibrillation (%) 8.9 10.2 0.89
Insulin (%) 66.7 —
Sulfonylureas (%) 57.7 —
Metformin (%) 35.1 —
Pioglitazones (%) 11.5 —
Metoprolol or
carvedilol (%)
92.3 86.5 0.20
ACE inhibitor or
ARB (%)
92.3 88.1 0.34
Digoxin (%) 52.6 42.8 0.47
Aspirin (%) 71.8 57.1 0.03
Statin (%) 70.9 57.5 0.08
Loop diuretics (%) 85.9 83.3 0.69
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker;
BMI body mass index; BNP B-type natriuretic peptide; CAD coronary artery
disease; CKD chronic kidney disease; Hgb hemoglobin; HgbA1c glycosylated
hemoglobin; HTN  hypertension; LVEF  left ventricular ejection fraction.
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contributed to the smaller difference in peak VO2 between diabetics
and nondiabetics in the Guazzi et al. (5) study. Glycosylated
hemoglobin was7% in every one of the Guazzi et al. (5) patients,
whereas it averaged 7.5% in our patients. Insulin therapy improves
peak VO2 in patients with diabetes and CHF (6,7). Diabetes is
associated with cardiac, vascular, metabolic, and skeletal muscle
alterations that all tend to reduce peak VO2 (8). High-energy
phosphate metabolism is impaired in skeletal muscles from pa-
tients with diabetes in the absence of CAD or LV dysfunction (2).
Phosphocreatinine loss, pH decline, and deoxygenation occur
sooner in exercising skeletal muscles of diabetics than in controls.
Alterations in energy metabolism contribute to reduce peak aerobic
capacity in CHF (9,10). The coexistence of diabetes and CHF may
further alter skeletal muscle energy metabolism and reduce peak
aerobic capacity. A major limitation of our study is the absence of
longitudinal data with tighter diabetes control.
In summary, diabetes negatively impacts on and is an indepen-
dent determinant of peak aerobic capacity in patients with CHF.
Diabetes needs to be taken into consideration when evaluating
functional capacity in patients with CHF.
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Left Ventricular Wall Motion Abnormalities Induced by Squatting:
A New Echocardiographic Stress Test for the Diagnosis of Coronary Artery Disease
To the Editor: Stress echocardiography is useful for diagnosing
coronary artery disease (CAD) (1,2). Expense, potential for com-
plications, and the time factor are potential disadvantages of these
techniques. Thus, there is a need for a simple, inexpensive, rapid,
and safe echocardiographic stress test.
Squatting increases left ventricular afterload and preload (3–5).
This study tested the hypothesis that squatting will produce left
ventricular wall motion abnormalities (WMA) in patients with
CAD.
The study population consisted of 15 normal male subjects
(group 1) (age range 34 to 75 years, mean 57 years) and 42 male
patients (mean age 63 years, range 31 to 84 years) who had
coronary angiography (group 2). The institutional committee on
human research approved the study protocol. Informed consent
was obtained from all subjects.
The standing (3 min of quiet standing) heart rate and blood
pressure were recorded. Parasternal long- and short-axis and apical
four-, two-, and three-chamber views were obtained in the
standing position. The subjects were asked to squat, for 2 min.
Blood pressure, heart rate, and echocardiograms were recorded.
The echocardiogram was repeated after standing.
A 16-segment model was used for analysis of echocardiographic
Figure 1. Individual peak oxygen uptake (peak VO2) values in diabetic
(DM) and nondiabetic (N-DM) patients with chronic heart failure due to
left ventricular systolic dysfunction. Mean peak VO2 is significantly lower in
DM than in N-DM patients.
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